US$ 25.17
fda glp-1 compounding warning september 2025 New project announcement: HHS‑OIG is taking a closer look at FDA's oversight of compounded GLP‑1 drugs. Although shortages ended in 2025, some facilities may still be producing these drugs at scale. Our FDA is moving to restrict
Description
And seeing the numbers creep up
[DOI] [PubMed] [Google Scholar] 15.Dez JJ, Iglesias P
Nathan DM (2022) Glycemia reduction approaches in type 2 diabetes: a comparative effectiveness (GRADE) study microvascular and cardiovascular outcomes

GLP-1 medications are eliminated through renal pathways, and reduced kidney function affects both drug tolerance and the risk of complications particularly dehydration-related acute kidney injury, which can occur when GI side effects (nausea, vomiting) reduce fluid intake

Side Effects and Safety: Injection vs

Data will be collected and managed using an electronic data capture (EDC) system designed for clinical research
